NCT06665828已完成1 期
A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN9533, a Monoclonal Antibody Against Factor XII, in Healthy Adults
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Incidence of Treatment Emergent Adverse Events (TEAEs)
研究概览
简要总结
The aim of this clinical trial is to see how safe and tolerable the clinical trial drug (REGN9533) is in healthy participants. This is the first time that REGN9533 will be given to humans.
After the clinical trial drug has been tested in healthy participants, future studies with REGN9533 will focus on participants with thromboembolic (blocking of blood vessels) diseases which include blood clots.
REGN9533 is a drug that is only used in clinical studies.
The clinical trial is looking at:
- The side effects REGN9533 might cause
- How much REGN9533 is in the blood at different times
- How the body reacts to REGN9533
- If the body makes antibodies to REGN9533 (unwanted immune response, which may cause REGN9533 to not work as well)
- What is the best dose of REGN9533
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Has a body mass index between 18 and 32 kg/m2, inclusive
- •Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of initial dose of study drug
- •Normal aPTT, normal PT, and normal platelet counts as described in the protocol
- •Hemoglobin values at screening period and at day -1 as described in the protocol
- •Negative Fecal Occult Blood Test (FOBT) during screening period
- •Normal Bleeding Time Test (BTT) at day -1 as defined by the study site
排除标准
- •History of any major surgical procedure or clinically significant physical trauma within the last 6 months that in the opinion of the investigator may pose a risk to the participant by study participation
- •History of clinically significant bleeding, requiring hospitalization or blood products within the last 6 months, that in the opinion of the investigator may pose a risk to the participant by study participation
- •History of bleeding diathesis (eg, including, but not limited to Hemophilia A or B, von Willebrand's Factor deficiency, fibrinogen deficiency, and other inherited or acquired bleeding disorders)
- •History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as assessed by the investigator, that may confound the results of the study or poses an additional risk to the participant by study participation
- •Is a current smoker including e-cigarettes or other nicotine-containing products; or is a former smoker including e-cigarettes or other nicotine-containing products which they have used at any time within 3 months prior to the screening visit
- •Has a confirmed positive drug test result at the screening visit and/or prior to randomization; or a history of recreational drug use (eg, marijuana) and/or drug or alcohol abuse within a year prior to the screening visit
- •Any malignancy, except for non-melanoma skin cancer or cervical/anus in-situ, that have been resected with no evidence of metastatic disease for 3 years prior to the screening visit
- •Has a history of significant multiple and/or severe allergies (eg, latex gloves), or has had an anaphylactic reaction to prescription or non-prescription drugs or food
- •Note: Other protocol-defined Inclusion/Exclusion Criteria apply
研究组 & 干预措施
REGN9533
Experimental
Randomized as described in the protocol Escalating Cohorts including Optional Cohorts
干预措施: REGN9533 (Drug)
Placebo
Experimental
Randomized as described in the protocol
干预措施: Matching Placebo (Drug)
结局指标
主要结局
Incidence of Treatment Emergent Adverse Events (TEAEs)
时间窗: Up to 100 days
Severity of TEAEs
时间窗: Up to 100 days
次要结局
- Change in activated Partial Thromboplastin Time (aPTT)(Baseline up to 100 days)
- Change in Prothrombin Time (PT)(Baseline up to 100 days)
- Concentrations of REGN9533(Up to 100 days)
- Incidence of Anti-drug Antibodies (ADAs) to REGN9533(Up to 100 days)
- Titer of ADAs to REGN9533(Up to 100 days)
研究者
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418Parkinson Disease PsychosisAmyotrophic Lateral Sclerosis (ALS)NCT059957821ST Biotherapeutics, Inc.64
已完成
1 期
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy AdultsFirst-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic StrokeNCT05636306NoNO Inc.83
已完成
1 期
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CHCV InfectionNCT01193478Gilead Sciences71
已完成
1 期
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsHealthyNCT05158335MBX Biosciences76
已完成
1 期
A Phase 1 Dose Escalation Study of VX-973 in Healthy AdultsPainNCT05866055Vertex Pharmaceuticals Incorporated30